共查询到20条相似文献,搜索用时 187 毫秒
1.
2.
北京市实施国家基本药物制度现状研究 总被引:1,自引:0,他引:1
为了全面了解北京市实施国家基本药物制度现状.从而进一步完善国家基本药物制度.使国家基本药物制度惠及更多的居民,从国家基本药物制度政策效应、国家基本药物使用结构、国家基本药物使用可负担性以及基本药物可及性方面对北京市实施国家基本药物制度现状进行分析.得出基本结论:北京市实施国家基本药物制度在相应的制度、机制建设方面,正呈现逐渐完善、不断规范的特点;城乡基本药物使用结构趋同;基本药物使用可负担性和可及性较好,品种维护工作需要进一步加强. 相似文献
3.
通过讨论基本药物制度的作用、制度实施后所暴露的问题和目前一些对于基本药物制度的看法,提出了实施该制度的必要性.并对于如何进一步完善国家基本药物制度提出了相关建议. 相似文献
4.
5.
6.
目的:为加快推进国家基本药物制度的全面实施和完善提出建议。方法:通过金坛市实施基本药物制度一年情况进行分析。结果和讨论:金坛市实施基本药物制度一年中,人民群众“看病贵”的现象得到了有效缓解,基层医疗卫生机构回归了公益性,公共卫生服务得到了明显加强,医务人员待遇得到了基本保障,但也暴露出了一些新问题,需要共同关注并加以完善和改进,以实现满足人民群众基本医疗用药制度。 相似文献
7.
"不忘本来"以患者为中心,提高群众的满意度;"吸收外来"借鉴世界卫生组织经验,赋予基本药物新内涵,构建基本药物制度新理念;"面向未来"完善基本药物制度政策体系,精准施策,协同推进。 相似文献
8.
正新一轮医改实施以来,基本药物制度作为国家基本医疗卫生服务制度立柱架梁的重要内容,发挥了积极作用。随着基本药物制度的不断覆盖和普及,实际工作中出现了不完全适应临床基本用药需求、短缺现象时有发生、质量参差不齐、与非目录药物界限越来越模糊等突出问题,使得基本药物制度何去何从遭受质疑。2018年9月,国务院办公厅印发《关于完善国家基本药物制度的意见》。这一业内简称"88号文"的《意见》一经 相似文献
9.
目的:完善国家基本罕见药物目录,保证群众对罕见药物的可获得性;方法:通过基本药物目录中的罕见病用药,分析我国罕见药的现状及其原因.结果:国家基本药物目录中罕见药种类极少,与基本药物的"可获得性"相差甚远.结论:我国急需从罕见药的法律地位、研究生产流通和费用支付机制政策方面入手,建立具有中国特色的罕见药制度. 相似文献
10.
11.
12.
基本药物制度问题浅析:以浙江省试点情况为例 总被引:1,自引:0,他引:1
以浙江省基本药物制度试行情况为例进行分析,认为基本药物要做到"有药可用、有药肯用、有钱能用",要积极鼓励基本药物的生产、流通和使用。 相似文献
13.
Providing affordable essential medicines to African households: the missing policies and institutions for price containment 总被引:2,自引:0,他引:2
Tetteh Ek 《Social science & medicine (1982)》2008,66(3):569-581
Medicines are integral of any healthcare system, and limited access to medicines undermines health systems' objectives of equity, efficiency and health development. In African countries, where it is estimated that 50-60% of the populace lack "access" to essential medicines, health problems associated with limited drug benefits are more damaging. However, there is no single solution to medicine access problem given its multiple dimensions: availability, acceptability, affordability and accessibility. This paper explores affordability dimension of medicine access and concentrates solely on price regulatory policies and institutional structures that national and international policy makers may consider in making prices of essential drugs compatible to the purchasing power of African households. The main theme is the application of the concept of bilateral dependence in creating price-sensitive purchasers to exert countervailing market power on drug price setting in African healthcare systems. 相似文献
14.
目的:对安徽省基层医疗卫生机构基本药物的实施效果进行比较分析,为进一步完善相关政策提供建议。方法:从可获得性、可负担性和合理用药三个方面确定关键指标收集数据,对基本药物实施效果进行前后比较分析。结果:改革后基层医疗卫生机构基本药物的配备率、配送率和使用率逐年递增,可获得性良好;但配送企业的利益难以保证,影响基本药物配送率。在可负担性方面,基本药物采购和零售价格明显下降,基本药物可负担性得到提升,但存在少数药品价格偏高的问题;处方用药行为得到改善,但注射剂处方率呈上升趋势。结论:对基本药物不同品种采取不同配送模式;加强政府监管,确保生产企业以合理价格中标;针对农村居民的用药需求制定特殊用药政策;开展合理用药的培训和宣传,确保药品的规范使用。 相似文献
15.
本文从理论、国际经验和趋势,以及中国现状,阐述整合医疗在医疗卫生改革中的重要性和作用。建议将整合医疗作为中国医改的战略选择,大力整合医疗卫生体系,建立公立医院之间、公立医院与城乡基层医疗卫生机构的分工协作机制,恢复三级医疗卫生网络,实行分级医疗、双向转诊的医疗服务模式,从根本上改变目前医疗卫生体系分割的局面,提高医疗卫生资源的利用效率,切实缓解群众"看病难、看病贵"的问题。 相似文献
16.
Background
The introduction of innovative specialty pharmaceuticals with high prices has renewed efforts by public and private healthcare payers to constrain their utilization, increase patient cost-sharing, and compel government intervention on pricing. These efforts, although rational for individual payers, have the potential to undermine the public health impact and overall economic value of these innovations for society. The emerging archetypal example is the outcry over the cost of sofosbuvir, a drug proved to cure hepatitis C infection at a cost of $84,000 per person for a course of treatment (or $1000 per tablet). This represents a radical medical breakthrough for public health, with great promise for the long-term costs associated with this disease, but with major short-term cost implications for the budgets of healthcare payers.Objectives
To propose potential financing models to provide a workable and lasting solution that directly addresses the misalignment of incentives between healthcare payers confronted with the high upfront costs of innovative specialty drugs and the rest of the US healthcare system, and to articulate these in the context of the historic struggle over paying for innovation.Discussion
We describe 3 innovative financing models to manage expensive specialty drugs that will significantly reduce the direct, immediate cost burden of these drugs to public and private healthcare payers. The 3 financing models include high-cost drug mortgages, high-cost drugs reinsurance, and high-cost drug patient rebates. These models have been proved successful in other areas and should be adopted into healthcare to mitigate the high-cost of specialty drugs. We discuss the distribution of this burden over time and across the healthcare system, and we match the financial burden of medical innovations to the healthcare stakeholders who capture their overall value. All 3 models work within or replicate the current healthcare marketplace mechanisms for distributing immediate high-cost events across multiple at-risk stakeholders, and/or encouraging active participation by patients as consumers.Conclusion
The adoption of these 3 models for the financing of high-cost drugs would ameliorate decades-long economic conflict in the healthcare system over the value of, and financial responsibility for, drug innovation. 相似文献17.
18.
基于全国基层医疗卫生机构的抽样调查、基层医疗机构门诊处方的抽样调查、典型省市专题调查与知情人访谈,本文对基本药物目录的更新调整、基本药物的供应保障、基本药物零差率与基层医疗机构经济补偿以及进一步推动国家基本药物制度的全面实施等方面提出了完善策略和政策建议。 相似文献
19.
20.
电子医疗数据已成为大数据时代开展药品安全主动监测的重要资源。基于此确认药品与不良事件是否存在关联,要回归传统的流行病学研究设计,选取恰当的对照进行对比。本文主要阐述不同对照选取的原理、适用情形,介绍、评价并比较各种对照选取的思路与参数,引入对照选择批量化实现的进展性成果,以期为我国利用电子医疗数据开展上市后药品安全性监测提供方法学参考。 相似文献